Efficacy and safety of tofacitinib treatment in Finnish patients with juvenile idiopathic arthritis: a real-life study
Authors' conclusion
In this real-life study involving 53 JIA patients, TOFA treatment was initiated consecutively and demonstrated effectiveness after 3 months, with no serious side effects reported.
Study context
- Population
- Consecutive juvenile idiopathic arthritis (JIA) patients starting tofacitinib, catchment area of Helsinki University Hospital, February 2022–October 202496% with prior treatment failure
- Participants
- 53 patients
- Outcome
- Effectiveness of TOFA treatment (disease activity by JADAS10, treatment efficacy), interruptions and reasons for discontinuation
Methodological detailsreal-life, consecutive patients, single-centre
- Real-life
- Consecutive patients
- Single-centre
Main finding
As reported in the abstract
JADAS10 and active joint counts · first 3 months
- Both JADAS10 scores and active joint counts decreased significantly during the first 3 months of tofacitinib (TOFA)
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Discontinuation of TOFA (Kaplan-Meier estimate) · 12-month follow-upKaplan-Meier estimate | TOFA 30% |
Original publication
Efficacy and safety of tofacitinib treatment in Finnish patients with juvenile idiopathic arthritis: a real-life study. Arthritis Res Ther. Published 31 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →